FY2030 Earnings Estimate for Invivyd Issued By HC Wainwright

Invivyd, Inc. (NASDAQ:IVVD) – Research analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Invivyd in a research report issued on Friday, January 23rd. HC Wainwright analyst P. Trucchio anticipates that the company will earn $1.16 per share for the year. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Invivyd’s current full-year earnings is ($1.64) per share.

IVVD has been the topic of several other reports. BTIG Research reissued a “buy” rating on shares of Invivyd in a report on Wednesday, January 21st. Zacks Research raised shares of Invivyd from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Invivyd in a research note on Monday, December 29th. D Boral Capital downgraded Invivyd from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 25th. Finally, D. Boral Capital reissued a “hold” rating on shares of Invivyd in a report on Tuesday, November 25th. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $8.00.

Invivyd Stock Down 2.8%

IVVD stock opened at $2.05 on Monday. Invivyd has a 52 week low of $0.35 and a 52 week high of $3.07. The business has a 50-day simple moving average of $2.42 and a 200 day simple moving average of $1.65. The company has a market cap of $477.90 million, a PE ratio of -4.36 and a beta of 0.61.

Invivyd (NASDAQ:IVVD) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The company had revenue of $13.13 million during the quarter, compared to analyst estimates of $12.00 million. Invivyd had a negative net margin of 119.63% and a negative return on equity of 92.97%.

Insiders Place Their Bets

In other Invivyd news, Director Kevin F. Mclaughlin purchased 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 19th. The shares were acquired at an average price of $2.50 per share, with a total value of $125,000.00. Following the transaction, the director owned 50,000 shares in the company, valued at $125,000. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 25.40% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Catalyst Funds Management Pty Ltd bought a new stake in Invivyd during the second quarter worth $27,000. Vanguard Personalized Indexing Management LLC boosted its holdings in Invivyd by 238.6% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock worth $29,000 after acquiring an additional 28,146 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Invivyd in the 4th quarter worth $33,000. Bank of America Corp DE raised its holdings in shares of Invivyd by 330.5% in the third quarter. Bank of America Corp DE now owns 49,252 shares of the company’s stock valued at $54,000 after purchasing an additional 37,811 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of Invivyd in the fourth quarter valued at about $60,000. Institutional investors own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.